Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan ab - entakapon; karbidopa (vattenfri); levodopa - filmdragerad tablett - 50 mg/12,5 mg/200 mg - entakapon 200 mg aktiv substans; levodopa 50 mg aktiv substans; karbidopa (vattenfri) 12,5 mg aktiv substans

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan ab - entakapon; karbidopa (vattenfri); levodopa - filmdragerad tablett - 200 mg/50 mg/200 mg - entakapon 200 mg aktiv substans; karbidopa (vattenfri) 50 mg aktiv substans; levodopa 200 mg aktiv substans

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan ab - entakapon; karbidopa (vattenfri); levodopa - filmdragerad tablett - 100mg/25 mg/200 mg - karbidopa (vattenfri) 25 mg aktiv substans; entakapon 200 mg aktiv substans; levodopa 100 mg aktiv substans

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan ab - entakapon; karbidopa (vattenfri); levodopa - filmdragerad tablett - 150 mg/37,5 mg/200 mg - karbidopa (vattenfri) 37,5 mg aktiv substans; entakapon 200 mg aktiv substans; levodopa 150 mg aktiv substans

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan ab - entakapon; karbidopa (vattenfri); levodopa - filmdragerad tablett - 75 mg/18,75 mg/200 mg - levodopa 75 mg aktiv substans; karbidopa (vattenfri) 18,75 mg aktiv substans; entakapon 200 mg aktiv substans

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan ab - klozapin - tablett - 100 mg - laktosmonohydrat hjälpämne; klozapin 100 mg aktiv substans

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan ab - klozapin - tablett - 25 mg - laktosmonohydrat hjälpämne; klozapin 25 mg aktiv substans

Europäische Union - Schwedisch - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europäische Union - Schwedisch - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiska medel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Schweden - Schwedisch - Läkemedelsverket (Medical Products Agency)

mylan ab - irbesartan - tablett - 150 mg - irbesartan 150 mg aktiv substans; laktosmonohydrat hjälpämne - irbesartan